Joubert‑Boutet‑Gomez Syndrome (JBGS)

Overview

Joubert‑Boutet‑Gomez Syndrome (JBGS) is a rare, genetically heterogeneous neurodevelopmental disorder characterized by a distinctive malformation of the brainstem and cerebellar vermis (the “molar tooth sign” on MRI), combined with variable multisystem involvement that may include intellectual disability, facial dysmorphism, renal anomalies, and ocular abnormalities. The syndrome was first described in 2002 as a phenotypic overlap between classic Joubert syndrome, the Boutet‑Cox ocular anomalies, and a set of gastrointestinal features later attributed to Dr. Gomez’s case series.

JBGS affects both males and females of all ethnicities. The exact prevalence is uncertain because it is often grouped with the broader “Joubert syndrome spectrum” (JSS). Current estimates suggest a prevalence of roughly 1 in 100,000–150,000 live births worldwide, with higher detection rates in regions with accessible genetic testing (e.g., North America, Europe, and parts of the Middle East).^[1][2]

Symptoms

Symptoms may appear at birth or become evident during early infancy. The severity and combination of features vary widely even within the same family.

Neurologic & Developmental

• Hypotonia – floppy muscle tone noted shortly after birth.
• Ataxia – unsteady gait and poor coordination that persist into childhood.
• Developmental delay – delays in gross motor, fine motor, speech, and social milestones.
• Intellectual disability – ranging from mild to moderate.
• Apnea & abnormal breathing patterns – episodic hyperpnea or periods of reduced breathing, especially during sleep.
• Seizures – reported in ~20% of patients, often focal or infantile spasms.

Ocular

• Coloboma of the retina or optic nerve.
• Abnormal retinal pigmentation.
• Strabismus (crossed eyes) and nystagmus.

Facial Dysmorphism

• Broad forehead, arched eyebrows.
• Deep-set eyes, epicanthal folds.
• Low-set, malformed ears.
• Flattened nasal bridge.

Renal & Urinary

• Nephronophthisis or cystic kidney disease (present in ~30% of cases).
• Hydronephrosis due to obstructive uropathy.

Other Systemic Features

• Polydactyly (extra fingers or toes) – often post‑axial.
• Liver fibrosis or cholestasis.
• Congenital heart defects (e.g., atrial septal defect) in <5% of patients.
• Gastro‑intestinal dysmotility causing feeding difficulties.

Causes and Risk Factors

JBGS is an autosomal‑recessive or, less commonly, X‑linked disorder caused by pathogenic variants in genes that encode proteins essential for primary cilia structure and function. The most frequently implicated genes are:

• TMEM67 – also linked to classic Joubert syndrome.
• TMEM237 – associated with the Boutet ocular phenotype.
• CEP290 – a major player in the broader Joubert spectrum.
• NPHP1 – contributes to renal manifestations.

Because these proteins are critical for ciliary signaling, mutations disrupt cellular communication during embryogenesis, leading to the characteristic brain, kidney, and eye abnormalities.

Risk Factors

• Consanguinity – higher incidence in families where parents are closely related.
• Family history – an affected sibling or parent who is a carrier increases risk.
• Ethnic clusters – certain variants are more prevalent in Arab, Ashkenazi Jewish, and some Asian populations.

Diagnosis

Diagnosing JBGS requires a combination of clinical, radiologic, and genetic assessments.

Clinical Evaluation

• Detailed prenatal or neonatal history, including birth weight, apnea episodes, and dysmorphic features.
• Developmental and neurologic examination.
• Ophthalmologic and renal screening.

Imaging Studies

• Brain MRI – the hallmark “molar tooth sign” (deepened interpeduncular fossa, thickened superior cerebellar peduncles, and cerebellar vermis hypoplasia).
• Renal ultrasound – assesses cystic disease or structural anomalies.
• Echocardiogram – indicated if cardiac murmurs or signs of congenital heart disease are present.

Genetic Testing

• Targeted gene panels for Joubert spectrum (TMEM67, TMEM237, CEP290, etc.).
• Whole‑exome sequencing (WES) – useful when panel results are negative.
• Carrier testing for parents when a pathogenic variant is identified.

Ancillary Tests

• Electroencephalogram (EEG) if seizures are suspected.
• Pulmonary function studies for chronic apnea evaluation.
• Serum liver function tests and urinalysis to monitor hepatic and renal involvement.

Treatment Options

There is no cure for JBGS; management focuses on symptom control, prevention of complications, and supportive therapies.

Neurologic & Developmental Care

• Physical therapy – improves muscle tone and balance.
• Occupational therapy – assists with fine motor skills and adaptive equipment.
• Speech‑language therapy – addresses language delays and feeding difficulties.
• Anticonvulsants – such as levetiracetam or valproic acid for seizure control.
• Respiratory support – CPAP or BiPAP for nocturnal apnea; in severe cases, tracheostomy may be considered.

Ophthalmologic Management

• Regular eye exams; corrective lenses for refractive errors.
• Surgical repair of retinal detachments or colobomas when indicated.

Renal & Hepatic Care

• Nephrology follow‑up; early use of ACE inhibitors to slow progression of cystic kidney disease.
• Liver monitoring; ursodeoxycholic acid for cholestasis.
• Kidney transplantation may be required in end‑stage renal disease (ESRD) – outcomes are comparable to other cystic kidney disorders.

Cardiac Intervention

• Medical management for minor defects; surgical repair for significant septal defects or valvular abnormalities.

Pharmacologic & Emerging Therapies

• Vismodegib – investigational cilia‐modulating drug currently in Phase II trials (clinicaltrials.gov NCT04577128).
• Gene‑therapy approaches (AAV‑mediated delivery) are under pre‑clinical investigation for CEP290‑related disease.

Lifestyle & Supportive Measures

• Nutrition: high‑calorie, easy‑to‑swallow diets; feeding tubes (gastrostomy) for severe dysphagia.
• Vaccinations: ensure up‑to‑date immunizations, especially influenza and pneumococcal vaccines to reduce respiratory infections.
• Family counseling and connection to patient advocacy groups (e.g., Joubert Syndrome Foundation).

Living with Joubert‑Boutet‑Gomez Syndrome

While JBGS is a lifelong condition, many individuals lead productive lives with appropriate support.

Daily Management Tips

• Routine monitoring – schedule quarterly visits with neurology, nephrology, and ophthalmology.
• Home safety – install handrails, non‑slip mats, and use adaptive utensils.
• Sleep hygiene – maintain a regular bedtime, use positional therapy for apnea, and keep a sleep diary.
• Educational planning – early intervention programs, individualized education plans (IEPs), and assistive technology (e.g., speech-generating devices).
• Psychosocial support – counseling for anxiety or depression which are common in chronic neurodevelopmental disorders.

Transition to Adult Care

As patients approach adulthood, a coordinated transfer to a multidisciplinary adult clinic is crucial. Focus shifts to fertility counseling, vocational training, and monitoring for late‑onset complications such as chronic kidney disease.

Prevention

Because JBGS is genetic, primary prevention centers on informed reproductive choices.

• Carrier screening for at‑risk populations (e.g., against TMEM67 and CEP290) before conception.
• Pre‑implantation genetic diagnosis (PGD) for couples undergoing in‑vitro fertilization.
• Prenatal testing – chorionic villus sampling or amniocentesis can detect known pathogenic variants.
• Genetic counseling is strongly recommended for families with a history of JBGS.

There are no lifestyle measures that prevent the syndrome once a pathogenic genotype is present.

Complications

If not adequately managed, JBGS can lead to serious health problems:

• Progressive renal failure – up to 40% develop ESRD by age 30.
• Severe respiratory insufficiency – due to central apnea or aspiration.
• Vision loss – from untreated coloboma or retinal detachment.
• Intellectual and psychosocial disability – may affect independence.
• Cardiac decompensation in those with congenital heart lesions.
• Recurrent infections – especially sinopulmonary infections secondary to aspiration.

When to Seek Emergency Care

---

References

1. Mayo Clinic. “Joubert syndrome.” Updated 2023. https://www.mayoclinic.org.
2. NIH Genetics Home Reference. “Joubert syndrome.” Accessed April 2024. https://ghr.nlm.nih.gov.
3. Cohen, R., et al. “The expanding Joubert syndrome spectrum: genotype‑phenotype correlations.” Orphanet Journal of Rare Diseases, 2022;17:45.
4. World Health Organization. “Rare diseases: global policy and action.” WHO Press, 2021.
5. Joubert Syndrome Foundation. “Clinical care guidelines.” 2023. https://www.joubert.org.
6. ClinicalTrials.gov. “Vismodegib for Ciliary Dysfunction in Joubert Spectrum Disorders.” NCT04577128. Updated 2024.